Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Collagen Type VIII alpha 1 (COL8A1) knockout mice have exacerbated choroidal neovascular lesions and incomplete response to anti-VEGF therapy
Author Affiliations & Notes
  • Xiaowu Gu
    Neuroscience, Genentech Inc, South San Francisco, California, United States
  • Tom Truong
    Translational Ophthalmology, Genentech Inc, South San Francisco, California, United States
  • Yann Malato
    Translational Ophthalmology, Genentech Inc, South San Francisco, California, United States
  • Shawnta Yvonne Chaney
    Translational Ophthalmology, Genentech Inc, South San Francisco, California, United States
  • Marion Jeanne
    Neuroscience, Genentech Inc, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Xiaowu Gu Genentech, Code E (Employment); Tom Truong Genentech, Code E (Employment); Yann Malato Genentech, Code E (Employment); Shawnta Chaney Genentech, Code E (Employment); Marion Jeanne Genentech, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2212. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaowu Gu, Tom Truong, Yann Malato, Shawnta Yvonne Chaney, Marion Jeanne; Collagen Type VIII alpha 1 (COL8A1) knockout mice have exacerbated choroidal neovascular lesions and incomplete response to anti-VEGF therapy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2212.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
Human genetics studies have identified risk loci and genetic variants associated with age-related macular degeneration (AMD), including several extracellular matrix related genes such as MMP9, TIMP3 and COL8A1. Collagen type VIII alpha 1 (COL8A1) and alpha 2 (COL8A2) are short-chain collagens expressed in many organs. While the COL8A1 gene has been genetically linked to AMD, the mechanism by which COL8A1 is potentially involved in the disease remains unknown. Here we examined the COL8A1 expression in human eyes, and investigated its function in AMD animal models.

Methods : COL8A1 and COL8A2 expression in control and AMD human eyes was examined by in situ hybridization. Col8a1 knockout (KO) and Col8a2 KO mice were generated using CRISPR technology. Littermates of wild-type (WT) and KO mice were subjected to the AMD preclinical models of laser induced choroidal neovascularization (CNV) with or without anti-VEGF treatment, and/or sodium iodate (NaIO3) induced retinal degeneration. CNV lesion sizes were quantified at day 7. NaIO3 lesions were longintudinally imaged by OCT and finally assessed by histology at day 21.

Results :
COL8A1 and COL8A2 are predominantly expressed in human retinal pigment epithelium (RPE) and COL8A1 expression is markedly increased in AMD lesions. In the CNV model, Col8a1 KO mice show significantly enlarged lesions compared to WT (p<0.0001). Col8a2 KO mice do not show change in lesion size (p = 0.587), while Col8a1/Col8a2 double KO mice have enlarged CNV lesions comparable to the Col8a1 single KO (p <0.0001 vs WT, p = 0.997 vs Col8a1 KO). Anti-VEGF antibody treatment effectively resolved CNV lesions in Col8a1 WT mice (76.5% of the lesions resolved), but provided only a partial therapeutic effect in the Col8a1 KO mice (19% of the lesions resolved). In the NaIO3 model, Col8a1 KO retinas show exacerbation of the subretinal lesions with increased retinal invagination occurrences (p<0.0001) and increased severity score (p = 0.002).

Conclusions :
COL8A1 is highly expressed in human RPE cells, especially in AMD lesions. Col8a1 loss in mice exacerbates AMD phenotypes such as choroidal neovascularization and subretinal lesions following RPE damage. Col8a1 KO mice also show incomplete response to anti-VEGF therapy and provide a new preclinical model to test new anti-neovascular therapeutic approaches.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×